WAY vs NVCR vs COLL vs KO vs INVA vs JPM

For growth investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger pick with 23. 6% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (6. 4x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Waystar Holding Corp. at 30. 7x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 4. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Collegium Pharmaceutical, Inc. wins at 0. 25x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -91. 9% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: JPM returned +465. 8% versus WAY's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately -1202% more volatile than KO relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Collegium Pharmaceutical, Inc.

(COLL) is pulling ahead at 23. 6% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -7. 0% for Collegium Pharmaceutical, Inc.. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Collegium Pharmaceutical, Inc. (COLL) is the more undervalued stock at a PEG of 0. 25x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Collegium Pharmaceutical, Inc. (COLL) trades at 4. 5x forward P/E versus 25. 3x for The Coca-Cola Company — 20. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.

In this comparison, KO (2.

5% yield), JPM (1. 9% yield) pay a dividend. WAY, NVCR, COLL, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, NVCR: +62. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WAY (Technology) and NVCR (Healthcare) and COLL (Healthcare) and KO (Consumer Defensive) and INVA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WAY is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; COLL is a small-cap high-growth stock; KO is a large-cap quality compounder stock; INVA is a small-cap high-growth stock; JPM is a large-cap deep-value stock. KO, JPM pay a dividend while WAY, NVCR, COLL, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.